Update on Rituximab: An Established Treatment for All Immune-Mediated Kidney Diseases?

Publisher： Karger

E-ISSN： 1660-2110|126|3|97-109

ISSN： 1660-2110

Source： Nephron Clin Pract, Vol.126, Iss.3, 2014-03, pp. : 97-109

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immune‐mediated diseases: what can be found in the oral cavity?

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 3, 2015-03 ,pp. : 258-270

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vernal Keratoconjunctivitis and immune‐mediated diseases: One unique way to symptom control?

By  

PEDIATRIC ALLERGY AND IMMUNOLOGY, Vol. 26, Iss. 3, 2015-05 ,pp. : 289-291

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genetic Variants in ERAP1 and ERAP2 Associated With Immune‐Mediated Diseases Influence Protein Expression and the Isoform Profile

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 70, Iss. 2, 2018-02 ,pp. : 255-265

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial (Thematic Issue: The Biologics in Clinical Practice: A Modern Approach for Inflammatory and Immune-Mediated Diseases)

By  

Current Drug Safety, Vol. 11, Iss. 1, 2016-03 ,pp. : 3-3

Bentham Science Publishers

Access to resources Recommend Favorite

Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases

By  

Current Drug Safety, Vol. 12, Iss. 3, 2017-10 ,pp. : 162-170

Bentham Science Publishers

Access to resources Recommend Favorite